

Introduction

Globally, healthcare is significantly challenged by rising antibiotic resistance, hospital-acquired infection, staff shortages, capital, and operational funding pressures. In deploying the Pharmafilter system, hospitals are removing the input of pharmaceuticals, including antibiotics, to the environment via hospital wastewater – a critical point in antibiotic stewardship. In addition, essential support services are automated, benefitting staffing, operations, efficiencies, economics, hygiene, patient and staff safety.

From waste management to water use to the near-zero carbon targets, Hospitals are operating under increasing environmental regulation at a time when demand for expert care is growing. Hospitals are required and expected to treat and care for patients while also contributing to a healthy society and sustainable environment. The decentralised Pharmafilter approach of combined on-site treatment of hospital waste and wastewater has proven environmental benefits while improving patient care.

The healthcare sector possesses a unique healing purpose. Yet, hospitals are key point sources for specialised pharmaceutical and microbiological residues entering the environment. It is a substantial source of contamination that can endanger ecosystems and the environment and accelerate the development of antimicrobial resistance (AMR) – a severe public health threat, previously predicted to kill over 10m people pa by 2050, however the World Health Organisation now believes this grim reality will be realised sooner.

Up to 90% of orally administered pharmaceuticals are excreted into wastewater as active substances in the faeces and urine of patients. This enables pharmaceuticals and their metabolites to be released into the aquatic ecosystem through hospital effluents. Due to technical and economic constraints, it is not possible to remove these contaminants at a receiving wastewater treatment plant because of the specialist removal techniques required.

Pharmaceuticals are, by design, intended to interact with living organisms, even low environmental concentrations are a concern. While conventional medicines are frequently consumed in the community, more specialised pharmaceutical products, e.g., cytostatic drugs, (restricted)antibiotics, and X-ray contrast agents, are principally administered in hospitals and clinics.

In addition, the generation of waste categories within a healthcare setting and the management and disposal of same, continues to generate unprecedented challenges in terms of increased volume and increasing costs for all concerned. Moreover, the global waste supply chain is undergoing transformative realignment and adjustment. Given ongoing environmental legislative reform, whereby healthcare risk waste is becoming restricted to the country or jurisdiction wherein it arises, placing limits for official shipping and movement for disposal around the globe, the Pharmafilter system is at the nucleus of resolving these challenges.

The Pharmafilter on-site system and operation method is a combined approach to efficiently and economically managing healthcare-generated wastes and wastewaters at the source. This aligns with established EU policy as it relates to Proximity and Self-Sufficiency Principles of the Waste Framework directive. Moreover, it future proofs client hospitals in relation to the evolution of the Water Framework Directive which in 2013, due to concerns around pharmaceutical inputs contributed to the EU amending the Water Framework Directive where:

“Diclofenac (CAS 15307-79-6), 17-beta-estradiol (E2) (CAS 50-28-2) and 17-alpha-ethinylestradiol (EE2) (CAS 57-63-6) shall be included in the first watch list, in order to gather monitoring data for the purpose of facilitating the determination of appropriate measures to address the risk posed by those substances.”

And,

“Pursuant to Article 16(9) of Directive 2000/60/EC, and where appropriate on the basis of the outcome of its 2013 study on the risks posed by medicinal products in the environment and of other relevant studies and reports, the Commission shall, as far as possible within two years from 13 September 2013 develop a strategic approach to pollution of water by pharmaceutical substances. That strategic approach shall, where appropriate, include proposals enabling, to the extent necessary, the environmental impacts of medicines to be taken into account more effectively in the procedure for placing medicinal products on the market. In the framework of that strategic approach, the Commission shall, where appropriate, by 14 September 2017 propose measures to be taken at Union and/or Member State level, as appropriate, to address the possible environmental impacts of pharmaceutical substances, particularly those referred to in Article 8b(1), with a view to reducing discharges, emissions and losses of such substances into the aquatic environment, taking into account public health needs and the cost-effectiveness of the measures proposed.”

(See article 8b of the 2013 Amendment to the Water Framework Directive)

This is the first time pharmaceutical substances have been included on a WFD watch list and the amendment clearly sets out the considerations under which future policy will be developed.


The on-site Pharmafilter plant *completely* eliminates hospital-specific contamination (pharmaceuticals, contrast media, cytotoxins, hormone disrupters, AMR pathogens, Covid 19, etc.) and other hazardous substances encountered in healthcare (Lab liquids/wastes, cleaning agents, etc.) in the wastewater treatment phase. Removal of these substances results in a pivotal decrease in the environmental footprint of the hospital.



The platform improves service delivery and achieves better outcomes for the hospital, its patients, staff, and the environment.

The Pharmafilter System is designed to: -

1. Substantially reduce waste and eliminate associated waste staffing and management costs.
2. Decontaminate and recycle water used by the hospital and reduce costs, up to 70% recycling possible.
3. Process and decontaminate all hospital-originating hazardous substances/materials, with none entering the environment.
4. Automate the transport and decontamination of hospital arising waste material.
5. Remove buffering, storing, and reduce internal waste movement throughout the hospital.
6. Enable cleaner, safer, more efficient working practice with the potential to render many parts of existing source segregation waste management procedures obsolete.
7. Create a platform to develop new approaches for reducing the risk of hospital-acquired infections, notably C.Diff, and improved efficiencies around Norovirus breakout. (HAI occurs at an incidence level of 7/8% in hospitals – Source)
8. Prevent the discharge of anti-microbials, pharmaceuticals, and other healthcare-specific contaminants micro-pollutants, and pathogens in hospital wastewater to public infrastructure. AMR and Covid 19.
9. Harvest energy from the organic fraction of the wastes processed on-site (Biogas).
10. Convert to energy the non-organic fraction of waste of high calorific value with 100% diversion from landfill. (RDF)
11. Develop data and critical information on waste, wastewater management, influent and effluent.
12. Future proof for legislation, increased associated cost including improved clinical cost-benefit opportunities.
13. Better and improved uses of resources and increased safety in related waste handling.
14. Reduction of truck movement servicing the waste.
15. When fully optimised, hospitals are supported and empowered to make real progress towards meeting carbon reduction targets and progressively improving their carbon and environmental footprint.



Hospital Wastewater

The wastewater of hospitals comprises a high concentration of pharmaceuticals, such as antibiotics, painkillers, cytotoxic substances, heart medicines, and contrast media. These substances are released through urine and faeces to the wastewater system and, despite excellent biological treatment in wastewater treatment plants, are ultimately discharged into surface water. It is now understood that these toxic and mutagenic compounds are responsible for disrupting water life and causing disease and malformation in water organisms through their hormone-disrupting activity, among others. At this moment, these kinds of substances are the emerging focus in environmental policy. Placing this issue high on the agenda, the World Health Organization (WHO) published a list of global priority pathogens (GPP) – identifying species of bacteria with critical, high, and medium antibiotic resistance (AR).

Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing variety of infections caused by bacteria, parasites, viruses, and fungi.



The EPA in Ireland in 2019, following a six-year study, published a report on antibiotic resistance as being a significant public health problem. In Ireland and most of Europe, hospital effluent is released into the urban wastewater system without any specific measurement of antibiotic levels of antibiotic-resistant bacteria and without any pre-treatment to mitigate the release of these pathogens into the aquatic environment (see "Hospital effluent: A reservoir for carbapenemase-producing Enterobacterales")

Hospitals are seen as a "hot-spot" of pharmaceutical emissions because there is a high load of pharmaceuticals used and emitted through hospital wastewater into local municipal sewerage.

Municipal wastewater treatment plants by design cannot deal effectively or economically with these challenging healthcare wastewaters. Nevertheless, they influence a condition which generates an opposite result -- as they provide a perfect environment and breeding ground for the multiplication of Anti-Microbial Resistant Bacteria, which finds its way into our environment.

Resulting from the Pharmafilter Treatment process, Wastewater is purified, and all drugs, micropollutants, and viruses are removed, including Antimicrobial Resistance Bacteria and Covid. The clean water is recycled for reuse -flushing toilets, waste shredders, etc. The waste is shredded and transported to the on-site plant through the existing wastewater pipework, decontaminated, and all treated waste fractions are utilised, recycled, repurposed, and organics converted to energy. The installation and deployment of the Tonto advanced intelligent shredders eliminate the need to segregate waste, including all the various collection bins, bags clogging wards, corridors, clinical spaces, and waste transport containers. It also reduces cross-infection, mis-sorting, damage to the buildings, and congestion.

Hospital Waste

Since 2008 Pharmafilter has operated in the Netherlands and is a complete, integrated waste and wastewater management solution. Which takes waste at the source (wards, consulting, dirty utilities, sluices rooms, and throughout a facility) and accepts and treats pharmaceuticals, swill, sewage, general refuse, clinical, and healthcare risk waste.

The Pharmafilter upstream or decentralised waste and wastewater treatment system significantly benefits the host hospital, the local community/municipality, and the environment. The treatment unit is designed to meet the complete decontamination requirements of the specific wastes generated in hospitals. This purpose-built system has none of the gaps or potential failures of more general designs or methods. This allows the hospital to eliminate the hazardous element of all waste exported offsite. Therefore, the hazardous material is neither transported through the local community nor shipped out of the country once treated by the Pharmafilter system, as is currently the case with some healthcare risk wastes. This particular supply chain (like others) is experiencing structural and legislative changes that create local and international bottlenecks.

Given that most hospitals are publicly funded and are required to meet government commitments regarding carbon emissions, opportunities to reduce the carbon footprint of operations are actively being explored. As the system incorporates an anaerobic digestion element, any organic fraction included in the waste stream is digested with the resulting biogas converted to energy to power the Pharmafilter plant. This digestion process, coupled with the shredding of material, dramatically affects the physical volume of the remaining residue. As a result, truck movements servicing waste is reduced by approximately 70%. (An exact number is difficult to project as a hospital may elect to maintain specific recycling streams or have a unique initial waste profile.) The effect on reducing national and international transport contributes to the hospital's carbon emission targets.

In this context, the Tonto's too have a decisive impact on carbon emissions. Conventional bedpan washers are installed to sterilise reusable bedpans. However, there is considerable dissatisfaction around this practice from infection control professionals with reusable bedpans, as it is considered unreliable in the context of a high-risk environment like a hospital ward. A combination of hot water and chemical decontamination is used in bedpan washers and sluices. The Tonto shredder is a cold-water process only and with inbuilt disinfectant capability for the waste compartment. It can take this approach, as decontamination for reuse is not required.

The system is a thoroughly integrated waste disposal and waste & wastewater decontamination system that at every stage delivers significant improvements in the handling, removal and treatment of waste streams arising from hospitals. It is a 'clean-technology' process for dealing with complex waste, sewage and wastewater.

Funding As a Service: Design-Build, Finance, Permit, Maintain, Operate and Own

Pharmafilter Group Holdings Ireland Ltd is the responsible entity for the business in Ireland and the UK. It provides the system on a fully financed "As a Service" basis, allowing the client to retain their capital budget for other uses. The "As a Service" basis to the Hospital or Health Service Authority is founded on an in-depth business case identifying areas of savings capable of being generated by the Pharmafilter system at each site. It delivers a lifetime operational framework for the client regarding finance, operations, project management, delivery, security of supply, insurances, KPI, environmental and statutory regulation, increased volume, and future emission limits. The engagement incorporates a complete turnkey solution including design, build, permit, maintenance, own and operation. This approach passes the long term Operational responsibilities unto Pharmafilter and significantly relieves the hospital's capital and associated operational budget pressure.



Procurement Public and Private

The Company and the solution have qualified for procurement in four separate contracting authorities in Ireland, Netherlands, Germany and, Switzerland. All procedures were robust and comprehensive and provided the CA with the required surety around the contracting counterparty- Pharmafilter, the system, supply structure, operations track record, and the capability to deliver and maintain the mandated services.

EPA Licensing and Building Permit

The EPA has granted the Pharmafilter solution its first Industrial Emissions license in Ireland and a building permit by Dublin County Council for a major project in Dublin Ireland.

The EPA has indicated that it has benefitted substantially from our application in terms of its understanding and knowledge base. Given that the systems processes are standard, future applications will also benefit from that experience.

Feasibility & Project approach

In conjunction with a potential client Hospital's staff, Pharmafilter investigates the suitability of its W&WW Treatment system as a comprehensive solution for waste and wastewater generated by the hospital. This assessment includes the ability to expand the system's capacity as the demands of the facility grow into the future, outside the initial stated capacity of the system. Over multiple site visits from both the civil and process engineering teams, measurements, massing and structural surveys, and desktop reviews of historical and current information are undertaken. These exercises are to confirm site suitability. Where site circumstances require solutions that deviate from the standard modular configuration (NB. but not process), more detailed preliminary engineering work is required. The system has been deployed in a non-standard in Erasmus MC in Rotterdam.

Contact

Patrick Gleeson | Chairman and Finance Pharmafilter GH Ltd
p.gleeson@pharmafilterltd.com
26 Upper Pembroke St, Dublin 2. | P +3531 6787666 M |+353 2546895
Berkeley Square House, Berkeley Square, London W1J 6BD | +44 203 869 1672

Peter McKeown | Country Manager Ireland Pharmafilter GH Ltd
p.mckeown@pharmafilterltd.com
26 Upper Pembroke St, Dublin 2. | P +3531 6787 666 M | +353 874152998
Berkeley Square House, Berkeley Square, London W1J 6BD | +44 203 869 1672

Peter Kelly | CEO Pharmafilter GH Ltd & CCO and Board Pharmafilter BV
p.kelly@pharmafilterltd.com
26 Upper Pembroke St, Dublin 2. | P +3531 6787 666 M |+353 86 8276649
Berkeley Square House, Berkeley Square, London W1J 6BD | +44 203 869 1672

Eoin Gleeson | Commercial Manager United Kingdom Pharmafilter GH
en.gleeson@pharmafilterltd.com
Berkeley Square House, Berkeley Square, London W1J 6BD | P +44 203 869 1672 M | +75 00 919 255
26 Upper Pembroke St, Dublin 2. | P +3531 6787 666 M | +75 00 919 255

www.pharmafilter.nl

"Circumstances for change are now upon us in how we manage Healthcare Waste and Wastewater. We must protect and play our part in restoring the healthcare climate balance by adopting innovative, financially viable, environmental and operational clinical advantageous technology". Pharmafilter Group Holdings Ltd.

"The Chief Executive of the UK Environment Agency, Sir James Bevan, is calling for more regulation not deregulation. We improve and protect the quality of our air, land and water by tackling pollution. We work with businesses to help them comply with environmental regulations and believe a healthy and diverse environment enhances people's lives and contributes to sustainable and resilient economic growth."

References

Cahill N, O'Connor L, Mahon B, Varley A, McGrath E, Ryan P, Cormican M, Breheony C, Jolley K.A, Maiden M.C. Brisse S, Morris D. 2019; Hospital effluent: A reservoir for carbapenemase-producing *Enterobacterales*? Science of the Total Environment. P 618-624



Pharmafilter

Waste and Wastewater Treatment for Healthcare

"Merging Health Tech - Clean Tech - Green Tech"

PHARMAFILTER FACILITIES



Pharmafilter



Erasmus MC
Universitair Medisch Centrum Rotterdam
Erasmus

